Among all definitions of sexual differentiation, we like the one from Wikipedia the best: 'Sexual differentiation is the process of development of the differences between males and females from an undifferentiated zygote (fertilized egg). As male and female individuals develop from zygotes into fetuses, into infants, children, adolescents, and eventually into adults, sex and gender differences at many levels develop: genes, chromosomes, gonads, hormones, anatomy, psyche, and social behaviors' . In sex development we can distinguish two different processes: sex determination that is the developmental decision that directs the undifferentiated embryo into a sexually dimorphic individual and sex differentiation that takes place once the sex determination decision has been made through factors produced by the gonads that determine the development of the phenotypic sex. At the beginning of gestation (1st and 2nd week) embryos of the two sexes differ only in their karyotypes. Starting at week 3, specific genes lead to the differentiation of the gonads which in turn produce hormones inducing anatomical and psychological differences and lead to behavioral differences that are ultimately influenced by the social environment. The main steps of intrauterine sex differentiation are depicted in figure 1 . At gestational weeks 6-7 the paramesonephric duct (Müllerian duct) develops next to the mesonephric duct. If testes develop and secrete testosterone,
WNT4 and Sex Development Sex Dev 2008; 2:210-218 211 the mesonephric (Wolffian) duct increases in size and differentiates into epididymis, vas deferens, and prostate. A glycoprotein secreted from the Sertoli cells, known as anti-Müllerian hormone (AMH) or Müllerian inhibiting substance (MIS), results in Müllerian duct regression. If testes do not develop, the mesonephric duct does not grow and eventually degenerates, whereas the paramesonephric duct proliferates and the fallopian tube, uterus, and upper third of the vagina develop ( fig. 2 ) .
In mammals, including humans, the differentiation of the gonads is the turning point of this whole process. The classical textbook theory says that in the presence of the sex determining region on the Y chromosome (SRY) , the default ovarian pathway of sex determination will be inhibited and therefore testes will be formed. In the XX individual, due to the absence of SRY , no inhibition of the default program will take place and ovaries will develop.
Ovarian determining factors might help the process of differentiation. However, these factors are yet to be determined. The second model, called the Z-factor theory, was proposed to explain the cases where XX individuals develop testes in the absence of SRY . According to this theory, the XX gonad expresses a factor that has both antitestis and pro-ovary function. SRY in XY individuals acts as an inhibitor of the Z-factor to lift the block on the male pathway. In this case, the bipotential gonad will differentiate into a testis [McElreavey et al., 1993] .
Although factors involved in male sexual differentiation have been well studied ( fig. 3 ), the pathways regulating female sexual differentiation remain incompletely defined. To date, no genes have been identified to play a similar role in ovarian development as it was shown for the SRY or SOX9 gene in testicular development. In mice, Wnt4, one of a few factors with a demonstrated function Fig. 4 . Wnt signaling cascade. When a WNT signal arrives at the cell surface, it stimulates the 'Frizzled' receptor and/or LDL-receptor related proteins 5 and 6 and arrow. This inhibits the degradation complex, blocking the elimination of ␤ -catenin. ␤ -Catenin migrates to the nucleus and stimulates expression of genes in concert with TCF. That in turn regulates embryonic induction, cell polarity, and cell fate. Apc: adenomatous polyposis of the colon; ␤ -Cat: ␤ -catenin; Ck1: casein kinase 1; Dvl: disheveled; Fz: frizzled; Gsk3: glycogen synthase kinase 3; Lrp: LDL-receptor related protein; TCF: T-cell transcription factor. From He et al. [2004] .
in the ovarian-determination pathway, has been found to be involved in sexual differentiation by suppressing male sexual differentiation, promoting Müllerian ducts differentiation, and maintaining oocyte health (see below).
WNT4 and Sex Development
WNT4 (wingless-type MMTV integration site family, member 4) is a member of the WNT family of secreted molecules that function in a paracrine manner to affect a number of developmental changes. Wnt proteins bind to members of the frizzled (Fz) family of cell surface receptors and possibly to the single-pass transmembrane protein LDL-receptor-related proteins 5 and 6 (Lrp5 and Lrp6) [He et al., 2004] . The binding of Wnt to Fz leads to activation of the phosphoprotein dishevelled (Dsh or Dvl). The activation and membrane recruitment of Dsh probably recruits Axin and the destruction complex to the plasma membrane, where Axin directly binds to the cytoplasmic tail of Lrp5/6. Axin is then degraded, which decreases ␤ -catenin degradation. The activation of Dsh also leads to the inhibition of Gsk3, which further reduces the phosphorylation and degradation of ␤ -catenin with consequent ␤ -catenin-dependent activation of Tcell factor/lymphocyte enhancer factor transcription factors, and induction of Wnt-responsive genes ( fig. 4 ) [Nusse, 2003] . Wnt proteins can also signal via a ␤ -catenin independent non-canonical pathway involving protein kinase C (Pkc) and c-Jun NH2-terminal kinase (Jnk) [Pandur et al., 2002] . (Readers interested in learning more about WNT proteins should visit the informative site http://www.stanford.edu/ ϳ rnusse/wntwindow.html).
Wnt4 is produced in ovarian somatic cells (pre-granulosa cells). It up-regulates Dax1 [Jordan et al., 2001 ], a gene known to antagonize the nuclear-receptor steroidogenic factor 1 and thereby inhibits steroidogenic enzymes. Vainio and collaborators [Vainio et al., 1999] observed in Wnt4 deficient mice that gonadal development and steroidogenic function were affected exclusively in female Wnt4 knockout mice, whereas both male and female mice had similar defects in kidney development and adrenal function. Wnt4 knockout female mice were masculinized, as demonstrated by the absence of Müllerian ducts and the presence of Wolffian ducts and expressed the steroidogenic enzymes 3 ␤ -hydroxysteroid dehydrogenase and 17 ␣ -hydroxylase, which are required for the production of testosterone and are normally suppressed in the developing female ovary. The ovaries of these mice also had less oocytes suggesting a role of Wnt4 in the life of female germ cells. This function is crucial for the organization of ovarian structure, since female germ cells have a central role in this process and in maintenance of the ovary, as demonstrated by the fact that when oocytes are either absent [Merchant, 1975] or lost after follicle formation [McLaren, 1984] , ovarian follicles never form or degenerate subsequently. In contrast, testis development proceeds in the absence of germ cells. WNT4 and follicostatin [Yao et al., 2004] appear to maintain oocyte viability once germ cells have reached their final destination in the gonad. Downstream of WNT4, two oocyte-specific transcription factors, among others, also play alpha critical role in oocyte survival: factor in the germline alpha (FIG␣, FIGLA) [Liang et al., 1997] and newborn ovary homeobox-encoding gene (NOBOX) [Rajkovic et al., 2004] . Absence of these genes results in oocyte death and prevents the subsequent formation of primordial follicles because of a failure of the ovigerous cords to become follicles [Soyal et al., 2000] . After FIG␣ has been activated in oocytes, another transcription factor, forkhead transcription factor FOXL2, is turned on to regulate the differentiation of somatic granulosa cells for folliculogenesis. Fbxw15/Fbxo12J , an F-box containing gene specifically expressed in mouse ovary, was recently shown to possibly contribute to ovarian physiology by preventing oocytes from exiting meiotic prophase or by regulating signaling events required for oocyte-granulosa cell communication [De La Chesnaye et al., 2008] . Bone morphogenic protein 15 (BMP15) and growth differentiation factor 9 (GDF9) are crucial for ovarian follicle physiology, probably by controlling its metabolism [Su et al., 2008] . In women, BMP15 and NOBOX mutations have been associated with premature ovarian failure [Di Pasquale et al., 2004 Dixit et al., 2006; Qin et al., 2007] , whereas GDF9 aberrant expression and genomic variants have been linked to premature ovarian failure and twin pregnancy, respectively [Chand et al., 2006; Palmer et al., 2006; Kovanci et al., 2007] . FOXL2 mutations have been associated to blepharophimosis/ptosis/epicanthus inversus syndrome (BPES) and premature ovarian failure [Harris et al., 2002] . Maintenance of follicle 'identity' is guaranteed by estrogen formation and action, as demonstrated by the transdifferentiation of normally formed ovarian tissue into testicular structures in mice lacking the enzyme aromatase (converting androgens to estrogens) [Britt and Findlay, 2003] and/or estrogen receptor [Couse et al., 1999; Dupont et al., 2000] . None of these factors, however, except maybe WNT4, have a similar role in ovarian development as SRY or SOX9 in testis differentiation. Figure 5 depicts this cascade.
WNT4 Deficiency: Implications for Human Sex Development
In humans, more copies of WNT4 , due to duplication of chromosome 1p31 ] p35, were found in a patient with ambiguous genitalia, severe hypospadias, fibrous gonads and remnants of both Müllerian and Wolffian ducts [Jordan et al., 2001 ], i.e., male-to-female sex reversal. On the other end of the spectrum, when both copies of the gene are inactive, as in the case of homozygote mutations, a severe clinical entity called the SERKAL syndrome results [Mandel et al., 2008] . The syndrome was described in three 46,XX fetuses and is characterized by female-tomale sex reversal with ambiguous genitalia, gonadal morphology ranging from ovotestis to normal testis, renal agenesis, adrenal hypoplasia, and pulmonar and cardiac abnormalities.
In the middle of such spectrum one might expect to find patients with intermediate defects of sex development. Searches for clinically relevant WNT4 mutations sometimes in large cohorts of such patients were unsuccessful [Domenice et al., 2004] . We described a woman with absent Müllerian structures (uterine and fallopian tubes) who had unilateral renal agenesis ( fig. 6 ) and clinical signs of androgen excess. Her phenotype resembles that of patients with the Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome and is also strikingly similar to that of Wnt4 knockout female mice. This constellation of findings prompted us to search for mutations in the WNT4 gene in this patient.
Direct sequencing of PCR-amplified exonic fragments revealed a heterozygous mutation leading to a heterozygous E226G/WT missense exchange in the WNT4 protein. In search for causes of the defective signaling, we found that the E226G mutant protein appears to be trapped inside the cell [Biason-Lauber et al., 2004] , likely because of defective post-translational lipid modification necessary for WNT proper function [Nusse, 2003] . Since any generalizations regarding the role of WNT4 in humans, however, must await the description and characterization of mutations in additional patients, we searched for additional subjects with WNT4 mutations. The recent identification of a second [Biason-Lauber et al., 2007] and a third patient [Philibert et al., 2008] with a similar phenotype and mutations in WNT4 (R83C and L12P, respectively) confirmed its role in ovarian and female reproductive tract development in women. The disease-causing WNT4 mutations are depicted in figure 7 . These additional patients also helped to refine the phenotype of WNT4 deficiency in humans. In fact, it appears that the absence of a uterus (and not other Müllerian abnormalities) and the androgen excess are the pathognomonic signs of WNT4 defects, suggesting that this might be a clinical entity distinct from the classical Mayer-Rokitansky-Kuster-Hauser syndrome. The functional studies performed in these cases suggested that the consequences of the present WNT4 mutations range from lack of lipid modification (and probable misfolding) [Biason-Lau- [Biason-Lauber et al., 2007] to defects in receptor binding [Philibert et al., 2008] . The fact that these patients are heterozygous and the results of the expression studies suggest that one normal copy of WNT4 is not only inadequate to maintain protein function, but is also negatively influenced by the mutant protein (dominant negative effect). Although this is not a classical gene-dosage phenomenon, since the gene copies are the same (except in the duplication case), it is certainly a dosage-sensitive sex determining process, as Jordan and coworkers already predicted [Jordan et al., 2001] . In fact, while too much WNT4 activity (duplication) induces feminization of the male, too little WNT4 activity (homozygous loss-of-function mutation) induces exactly the opposite, i.e., masculinization of the female. Since WNT4 inhibits the male development in the female and males do not need WNT4 for their sex development [Vainio et al., 1999] , situations between these two extremes are characterized by different degrees of masculinization of the female. Although the presence of negative dominance renders the case arithmetically more complex, the relationship between activity levels and phenotype of WNT4 abnormalities is rather striking ( fig. 8 ) and corroborates the idea that sex differentiation is a matter of dosage. A general view of the role of WNT4 in sexual development is depicted in figure 9 .
Conclusions
The idea that the female sexual development happens by default was born in the middle of the last century after Jost [1970] carried out his innovative experiments to study the bases of differentiation of the reproductive tract and was based on the fact that the female reproductive tract develops even in the absence of any gonad. The term default (passive), attributed to the ovarian developmental pathway, therefore established itself even if it was not originally so intended.
However, recent findings have demonstrated that ovarian development in its early stages is an active process. The role of WNT4 (and follicostatin) in this process is to suppress the migration of mesonephric endothelial and steroidogenic cells preventing the formation of malespecific coelomic blood vessels and the production of steroids [Jeays-Ward et al., 2003; Yao et al., 2004] . Furthermore, Wnt4 appears to protect the germ cells in mice [Vainio et al., 1999] and probably in humans [Philibert et al., 2008] .
Although Wnt4/follicostatin has an anti-testis (anticoelomic vessel) and a pro-ovarian action (germ cell protection), they do not fit to the Z-factor profile because they influence a marginal aspect of testicular differentiation. Nevertheless, these anti-testis/pro-ovary properties and the fact that WNT4/follicostatin are made by somatic cells (similar to what happens for male-specific factors in the testis) render the WNT4/follicostatin duo an intriguing candidate for the role of the ovarian determining factor. Also, it is appealing to us and others in the field [Yao, 2005] to speculate that the development of testicular structures in XX individuals who do not have SRY or any activation of its down-stream targets, points to the possibility that maybe the development of testes is the default pathway.
From a more clinical point of view, we agree with Clement-Ziza et al. [2005] that it should not be looked for WNT4 mutations in MRKH syndrome. However, MRKH-like syndromes associated with hyperandrogenism should be investigated for mutations in this gene and may classify for a distinct clinical entity. 
Future Perspectives
Given the role of WNT4 in the maintenance of the female phenotype of the ovaries, polymorphisms or milder defects of this gene and dysregulation of protein function are obvious candidates for functional hyperandrogenic states such as polycystic ovary (PCO) disease. The altered expression of components of WNT signaling in PCO theca cells (demonstrated by gene expression profiling) [Wood et al., 2004] suggests an inhibition of the pathway and adds further weight to this idea. Thus, there is a need for a better characterization of the WNT4 signaling pathway in ovarian tissues in order to estimate its potential contribution to functional hyperandrogenic states. Mod- [Jordan et al., 2001 ]; b [Biason-Lauber et al., 2004 Philibert et al., 2008] ; c [Mandel et al., 2008] . ulation of WNT4 signaling may turn out to be beneficial in the treatment of polycystic ovary disease or other forms of hyperandrogenism in future.
Animal experiments demonstrated that a major role of Wnt4 in adrenal development is to prevent the gonadal programming of the adrenal cortex. An additional function might also include the maintenance of a functional zona glomerulosa, because aldosterone production in Wnt4 -/-mice is significantly reduced [Heikkila et al., 2002] . Wnt4 is thought to act by inhibiting the synergy between ␤ -catenin and Sf-1 on its targets in vitro [Jordan et al., 2003 ] suggesting a role in noncanonical Wnt signaling in adrenals. Although in adult human adrenal glands WNT4 is the only member of the WNT family to be ex-pressed [Suwa et al., 2003] , there is no evidence of impaired aldosterone secretion in WNT4 deficient heterozygous patients (normal aldosterone levels, normal PRA, normal electrolytes). The homozygous deficient fetuses had smaller adrenals (as in mice), but no biochemical studies are available. This might be due to species-specific differences or to the fact that the identified mutations do affect the canonical pathway, but not the noncanonical. The role of canonical and non-canonical WNT4 signaling in human adrenals, with focus on aldosterone production, needs yet to be explored and could have implications for the regulation of salt-water balance and hypertension. One could even speculate that certain polymorphisms of WNT4 may predispose to or protect against the development of essential hypertension.
